GEA
GWPH

Glen Eagle Advisors’s GW Pharmaceuticals Plc American Depositary Shares GWPH Stock Holding History

Glen Eagle Advisors’s Portfolio GWPH Stock Details GWPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-124
Closed -$26.9K – 1070
2021
Q1 		$26.9K Sell
124
-36
-23% -$6.77K 0.01% 459
2020
Q4 		$18.5K Hold
160
– – 0.01% 512
2020
Q3 		$15.6K Buy
160
+36
+29% +$4.14K 0.01% 508
2020
Q2 		$15.2K Buy
+124
New +$14.1K 0.01% 486
2018
Q2 		– Sell
-60
Closed -$6.76K – 710
2018
Q1 		$6.76K Hold
60
– – 0.01% 490
2017
Q4 		$7.92K Hold
60
– – 0.01% 465
2017
Q3 		$6.09K Sell
60
-60
-50% -$6.43K 0.01% 494
2017
Q2 		$12K Buy
120
+5
+4% +$538 0.01% 367
2017
Q1 		$13.9K Buy
115
+90
+360% +$11K 0.01% 330
2016
Q4 		$2.79K Buy
+25
New +$3.01K ﹤0.01% 480

Other funds holding GWPH

HDIM
Hanson & Doremus Investment Management Burlington, Vermont $869M AUM 23.62% 1-Year Est. Return

Glen Eagle Advisors's GWPH Position: Q2 2021 in Review

Glen Eagle Advisors sold out of GW Pharmaceuticals Plc American Depositary Shares (GWPH) in Q2 2021, closing a stake of 124 shares — an estimated $26.9K sold.

Glen Eagle Advisors first reported a position in GWPH in Q4 2016 and held it in 10 quarters. The position peaked at $26.9K in Q1 2021. 1 fund tracked by Wall St. Rank holds GWPH as of Q2 2021.

  • Glen Eagle Advisors reported no remaining GW Pharmaceuticals Plc American Depositary Shares position as of Q2 2021 after selling out during the quarter.
  • Glen Eagle Advisors sold 124 GW Pharmaceuticals Plc American Depositary Shares shares in Q2 2021, an estimated $26.9K.
  • Glen Eagle Advisors first reported a position in GW Pharmaceuticals Plc American Depositary Shares in Q4 2016 and held it in 10 quarters.
  • Glen Eagle Advisors's GW Pharmaceuticals Plc American Depositary Shares position peaked at $26.9K in Q1 2021.
  • 1 fund tracked by Wall St. Rank held GW Pharmaceuticals Plc American Depositary Shares as of Q2 2021.

Based on Glen Eagle Advisors's 13F filing for Q2 2021, filed 13 Aug 2024.